Trial Profile
Efficacy and safety of meningococcal vaccine group B OMV in healthy subjects.
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 19 Feb 2015
Price :
$35
*
At a glance
- Drugs Meningococcal vaccine group B OMV Novartis (Primary) ; Meningococcal vaccine group B OMV
- Indications Meningococcal infections
- Focus Pharmacodynamics
- 05 Nov 2010 New trial record.
- 26 Jan 2005 Results of pooled analysis of four trials published in the Vaccine.